Show simple item record

dc.contributor.authorBesse, B.en
dc.contributor.authorPaz-Ares, L. G.en
dc.contributor.authorPeters, S.en
dc.contributor.authorCappuzzo, F.en
dc.contributor.authorReck, M.en
dc.contributor.authorCalles, A.en
dc.contributor.authorCalifano, Raffaeleen
dc.contributor.authorLopez-Vilarino, J. A.en
dc.contributor.authorVeramendi, S.en
dc.contributor.authorKahatt, C. M.en
dc.contributor.authorZeaiter, A. H.en
dc.contributor.authorSands, J.en
dc.date.accessioned2023-10-25T08:48:39Z
dc.date.available2023-10-25T08:48:39Z
dc.date.issued2023en
dc.identifier.citationBesse B, Paz-Ares LG, Peters S, Cappuzzo F, Reck M, Calles A, et al. A phase III study of lurbinectedin alone or in combination with irinotecan vs investigator's choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial). Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772005484.en
dc.identifier.doi10.1200/JCO.2023.41.16_suppl.TPS8613en
dc.identifier.urihttp://hdl.handle.net/10541/626663
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2023.41.16_suppl.TPS8613en
dc.titleA phase III study of lurbinectedin alone or in combination with irinotecan vs investigator's choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentInstitut Gustave Roussy, Villejuif, Franceen
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record